Health Topics

Quest adds new biomarker test to Alzheimer's portfolio
By LabPulse.com staff writers
Quest Diagnostics has launched a new blood biomarker test as part of its AD-Detect portfolio of blood tests for Alzheimer's disease risk assessment.
April 23, 2024
Amyloid Plaque Alzheimer Social
Target ALS launches new data portal for research
By Matt Limb
A nonprofit medical research foundation has launched a data portal designed to help spur scientific breakthroughs for the disease amyotrophic lateral sclerosis (ALS).
April 23, 2024
Dna Data Ai Social
Roche, Lilly Alzheimer's blood test granted FDA breakthrough device designation
By LabPulse.com staff writers
The Alzheimer's blood test developed through a collaboration between Roche and Lilly has been granted a breakthrough device designation by the U.S. Food and Drug Administration (FDA).
April 11, 2024
Alzheimers Tau Tangles Social
Skin biopsy test shows promise for detection of neurogenerative diseases
By Matt Limb
A simple skin biopsy test has shown a high accuracy rate in detecting an abnormal form of alpha-synuclein, the pathological hallmark of Parkinson's disease and other synucleinopathies, say neurologists.
April 5, 2024
Parkinsons Neuron Social
U.K. team develops new approach to detect signs of motor neuron disease
By Matt Limb
Scientists have identified a new way to detect signs of motor neuron disease (MND) in brain tissue, raising hopes for early diagnosis and intervention before onset of symptoms.
April 3, 2024
Nerve Neuron Axon Social
Bluebird Bio secures up to $175M in debt financing
By LabPulse.com staff writers
Bluebird Bio has secured up to $175 million in debt financing with Hercules Capital, having entered into a five-year term loan facility that provides funds in separate tranches.
March 18, 2024
Research Money Social
FDA updates draft guidance for Alzheimer's drug development biomarkers
By LabPulse.com staff writers
The U.S. Food and Drug Administration (FDA) has released an updated draft guidance for the use of biomarkers aimed at sponsors and pharmaceutical companies developing drugs intended to treat early Alzheimer's disease.
March 14, 2024
Amyloid Plaque Alzheimer Social
Bluebird Bio signs state Medicaid agreement for SCD gene therapy
By LabPulse.com staff writers
Bluebird Bio has signed its first outcomes-based Medicaid agreement for its sickle-cell disease (SCD) gene therapy Lyfgenia with the state of Michigan.
March 11, 2024
Sickle Cell Anemia2 Social
Eisai invests $15M in C2N to increase Alzheimer's test access
By LabPulse.com staff writers
C2N Diagnostics has announced that pharmaceutical company Eisai has agreed to invest up to $15 million in C2N to provide broader access to Alzheimer’s disease tests.
March 6, 2024
Amyloid Plaque Alzheimer2 Social
Alzheimer’s study results show correlation between blood-based biomarkers and amyloid plaques
By LabPulse.com staff writers
The first results from the Bio-Hermes study have been released, showing a strong correlation between several blood-based and digital biomarkers with the presence of amyloid plaques in the brain, a diagnostic hallmark of Alzheimer's disease (AD).
March 1, 2024
Amyloid Plaque Alzheimer2 Social
Study: Novel type of inhibitor may prevent microvascular diabetic complications
By Matt Limb
A new type of inhibitor drug could prevent microvascular diabetic complications, such as diabetic eye and kidney disease, research suggests.
February 15, 2024
Diabetes Insulin Glucose Blood Social
NHS lacks capacity for Alzheimer’s diagnostics, warn experts
By Matt Limb
Many thousands of patients in the U.K. could miss out on new treatments for Alzheimer’s disease because its National Health Service (NHS) lacks capacity for diagnostic tests, warn experts.
February 14, 2024
Amyloid Plaque Alzheimer2 Social
Page 1 of 69
Next Page